Jennifer L Busby

US Patent:

20230020089, Jan 19, 2023

Filed:

May 4, 2022

Appl. No.:

17/736738

Inventors:

- Emeryville CA, US
Raphael Rousseau - Los Altos CA, US
Roman Yelensky - Newton MA, US
James Xin Sun - Newton MA, US
Matthew Joseph Davis - Scituate MA, US
Karin Jooss - Emeryville CA, US
Amy Rachel Rappaport - Daly City CA, US
Ciaran Daniel Scallan - San Francisco CA, US
Leonid Gitlin - Foster City CA, US
Christine Denise Palmer - Cambridge MA, US
Jennifer Busby - Burlington MA, US
Mojca Skoberne - Cambridge MA, US
Wade Blair - Gaithersburg MD, US

International Classification:

A61K 39/00
A61P 35/00
C12N 15/86
C12N 15/62

Abstract:

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccincation strategy.

US Patent:

20210147550, May 20, 2021

Filed:

Aug 17, 2018

Appl. No.:

16/639073

Inventors:

Joshua Michael FRANCIS - Emeryville CA, US
Gijsbert Marnix GROTENBREG - Emeryville CA, US
- Emeryville CA, US
Jennifer Busby - Emeryville CA, US
Michele Anne Busby - Emeryville CA, US
Joshua Michael Francis - Emeryville CA, US
Gijsbert Marnix Grotenbreg - Emeryville CA, US
Mojca Skoberne - Emeryville CA, US
Roman Yelensky - Emeryville CA, US

International Classification:

C07K 16/28
C07K 14/725
G01N 33/574

Abstract:

Provided herein are HLA-PEPTIDE targets and antigen binding proteins that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets as well as identifying one or more antigen binding proteins that bind a given HLA-PEPTIDE target.

US Patent:

20210061914, Mar 4, 2021

Filed:

Dec 28, 2018

Appl. No.:

16/958615

Inventors:

- Emeryville CA, US
Wade Blair - Emeryville CA, US
Michele Anne Busby - Emeryville CA, US
Jennifer Busby - Emeryville CA, US
Joshua Michael Francis - Emeryville CA, US
Gijsbert Marnix Grotenbreg - Emeryville CA, US
Mojca Skoberne - Emeryville CA, US
Roman Yelensky - Emeryville CA, US

International Classification:

C07K 16/28
C07K 14/725
C07K 14/705

Abstract:

Provided herein are HLA-PEPTIDE targets and antigen binding proteins that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets as well as identifying one or more antigen binding proteins that bind a given HLA-PEPTIDE target.

US Patent:

20200411135, Dec 31, 2020

Filed:

Feb 27, 2019

Appl. No.:

16/975823

Inventors:

- Emeryville CA, US
Jennifer Busby - Emeryville CA, US
Mojca Skoberne - Emeryville CA, US
Roman Yelensky - Emeryville CA, US

International Classification:

G16B 20/20
G16B 30/20
G16B 40/00

Abstract:

A method for identifying neoantigens that are likely to be presented by MHC alleles on a surface of tumor cells of a subject. Peptide sequences of the tumor neoantigens and of the MHC alleles are obtained by sequencing the tumor cells of the subject. The peptide sequences of the tumor neoantigens and of the MHC alleles are input into a machine-learned presentation model to generate presentation likelihoods for the tumor neoantigens, each presentation likelihood representing the likelihood that a neoantigen is presented by at least one of the MHC alleles on the surface of the tumor cells of the subject. A subset of the neoantigens is selected based on the presentation likelihoods.

US Patent:

20200105377, Apr 2, 2020

Filed:

Jun 8, 2018

Appl. No.:

16/619652

Inventors:

- Emeryville CA, US
Roman Yelensky - Emeryville CA, US
Jennifer Busby - Emeryville CA, US
Adnan Derti - Emeryville CA, US

International Classification:

G16B 40/10
G16B 30/00
G16B 20/00
G16H 20/00
G16H 50/30
G16H 10/40
G16H 10/60
G06N 20/00

Abstract:

Disclosed herein is a system and methods for determining the alleles, neoantigens, and vaccine composition as determined on the basis of an individual's tumor mutations. Also disclosed are systems and methods for obtaining high quality sequencing data from a tumor. Further, described herein are systems and methods for identifying somatic changes in polymorphic genome data. Further, described herein are systems and methods for selecting a subset of patients for treatment. A utility score indicating an estimated number of neoantigens presented on the surface of tumor cells is determined for each patient based on one or more neoantigen candidates identified for the patient. The subset of patients are selected based on the determined utility scores. The selected subset of patients can receive treatment, such as neoantigen vaccines or checkpoint inhibitor therapy. Finally, described herein are unique cancer vaccines.